Emcure Pharmaceuticals · NSE: EMCURE · BSE: 544210
Q1 FY27 results · Apr–Jun 2026
Emcure Pharmaceuticals reported revenue from operations of ₹2,580.45 crore (up 22.8% from Q1 FY26) and net profit of ₹292.49 crore (up 36.2% from Q1 FY26) for Q1 FY27 (Apr–Jun 2026), on a consolidated basis.
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,580.45 | 2,100.54 | +22.8% | 2,469.70 | +4.5% |
| Other income | 2.07 | 3.70 | −44.0% | 3.99 | −48.1% |
| Total income | 2,582.52 | 2,104.23 | +22.7% | 2,473.70 | +4.4% |
| Profit before tax | 393.53 | 290.76 | +35.3% | 341.18 | +15.3% |
| Net profit for the period | 292.49 | 214.79 | +36.2% | 243.74 | +20.0% |
| Attributable to shareholders of the company | 293.98 | 206.95 | +42.1% | 243.40 | +20.8% |
| EPS, basic (₹) | 15.50 | 10.92 | +41.9% | 12.84 | +20.7% |
| Net margin (%) | 11.3 | 10.2 | 9.9 |
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,450.93 | 1,096.57 | +32.3% | 1,467.70 | −1.1% |
| Other income | 25.03 | 21.52 | +16.3% | 26.94 | −7.1% |
| Total income | 1,475.96 | 1,118.10 | +32.0% | 1,494.64 | −1.2% |
| Profit before tax | 268.67 | 165.67 | +62.2% | 306.27 | −12.3% |
| Net profit for the period | 200.11 | 122.79 | +63.0% | 233.70 | −14.4% |
| EPS, basic (₹) | 10.55 | 6.48 | +62.8% | 12.33 | −14.4% |
| Net margin (%) | 13.8 | 11.2 | 15.9 |
Consolidated
- Filed with BSE
- 06 Aug 2026, 14:57 IST
- Board meeting
- 06 Aug 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 06 Aug 2026, 14:57 IST
- Board meeting
- 06 Aug 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE